NCT06061952View on ClinicalTrials.gov

CAE for Poorly Adherent Individuals With Schizophrenia

NACompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

January 16, 2024

Primary Completion Date

August 9, 2025

Study Completion Date

August 9, 2025

Conditions
Schizophrenia
Interventions
BEHAVIORAL

Customized Adherence Enhancement for Schizophrenia (CAE-S)

6-session series spaced out over approximately 6-10 weeks

OTHER

Enhanced Treatment as Usual (eTAU)

eTAU participants will view a pre-taped series of 6 videos

Trial Locations (1)

44106

University Hospitals Cleveland Medical Center, Cleveland

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

University Hospitals Cleveland Medical Center

OTHER

NCT06061952 - CAE for Poorly Adherent Individuals With Schizophrenia | Biotech Hunter | Biotech Hunter